《麦肯锡出品中国医院药品报告》由会员分享，可在线阅读，更多相关《麦肯锡出品中国医院药品报告（48页珍藏版）》请在金锄头文库上搜索。
1、CPA-McKinsey China Hospital Pharmaceuticals Report: An In-depth Perspective February 2014 Report CPA-McKinsey China Hospital Pharmaceuticals Report: An In-depth Perspective CPA-McKinsey Report February, 2014 About this report Context for this report The CPA-McKinsey report is published by a joint re
2、search team established by the Science and Technology Development Center of the Chinese Pharmaceutical Association (DCSTCPA) and McKinsey Tier 2 has 46 cities (e.g., Tianjin, Nanjing, Hangzhou, Wuxi, and Wenzhou); Tier 3 has 211 cities (e.g., Lanzhou, Guiyang, and Shantou); Tier 4 has 554 cities, (e
3、.g., Penglai, Yanji, and Longhai). The rest of China is classified as county/rural. (See Appendix 1) The therapeutic areas in this report are classified according to the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system. The analyses in Section II are based
4、on data from 752 sample hospitals in 30 selected provinces. This represents an increase from the 650 sample hospitals in 28 provinces that were included in last years report. The analyses in Section III are based on 508 sample hospitals that purchase biologics products. The majority of the sample ho
5、spitals are Class III and Class II hospitals. (See Appendix 2) DCSTCPA and McKinsey hold the proprietary rights to this report. Any use of this material without written permission from both parties is strictly prohibited. Key messages Chinas overall hospital pharmaceutical market is expected to reac
6、h around RMB 500 billion in value in 2013; the year-on-year growth rate slowed from 22% for the period from 2008 to 2012 to 12% in 2013 Class III hospitals account for 61% of the total hospital pharmaceutical market sales, with a CAGR of 22% from 2008 through 2013 Tier 2 and 3 cities represent 58% o
7、f total sales; Tier 1 cities are growing more slowly than the rest of the market At the sample hospitals, CPA data (for hospital procurement) show that the market grew 11% from Q3 2012 through Q3 2013, representing an increase of RMB 4.5 billion in absolute value. This growth rate is notably higher
8、than the 1% growth in ex-manufacturer sales reported by pharmaceutical companies for the same period. These findings suggest that the increased government scrutiny of commercial practices, which started in Q3 2013, did not affect hospital purchasing volume to the same extent as ex-manufacturer sales
9、 The overall biologics market in the hospital channel has grown at a CAGR of 21% since 2010 and reached RMB 25 billion in value in 2013 The complex biologics segment accounts for 16% of the total biologics market in the hospital channel; it grew at a CAGR of 30% from 2010 through 2013. The market is
10、 very concentrated, with 15 leading hospitals accounting for about 50% of complex biologics sales within the 508 sample hospitals In the complex biologics segment, oncology is the largest TA, with a 73% value share, while immunology TA has a 15% share and other TAs take a 12% share The less complex
11、biologics segment is relatively mature and the technological barrier to enter this market is lower. Generally speaking, the more “mature” the technology is, the more competitive the market and the higher the local share Chinas hospital pharmaceutical market Biologics market at a glance Table of cont
12、ent Overview of Chinas hospital pharmaceutical market 1 Analysis of market leaders and major therapeutic areas 5 Biologics market deep-dive 11 1 Chinas overall hospital pharmaceutical market had a value of RMB 444 billion in 2012 and is expected to be valued at 500 billion in 2013: Chinas overall ho
13、spital pharmaceutical market is expected to reach a value of RMB 499 billion in 2013 The market grew at a CAGR of 22% from 2008 to 2012; the annual growth rate dropped to 12% in 2013 203 0 50 100 150 200 250 300 350 400 450 500 +20% +12% +19% +22% +25% 2013E 499 +55 2012 444 +72 2011 372 +62 2010 31
14、0 +57 2009 253 +50 2008 Sales in Chinas hospital pharmaceutical market 1 RMB billions SOURCE: China Pharmaceutical Association; NHFPC statistical yearbook; McKinsey analysis 1 Market size extrapolated based on CPA sample hospital pharmaceutical sales, using ex-trade prices Exhibit 1.1 Section I: Chi
15、nas hospital pharmaceutical market 2 From a hospital-class viewpoint, Class III hospitals still account for the largest share of the pharmaceutical market: Class III hospitals take 61% share of the market, and growth in this areas outpaces that of other segments Class II hospitals represent 34% of t
16、he market, while Class I hospitals represent 5% of the market; both have lower growth rates 350 300 250 200 150 100 50 0 2013E 499 25 169 304 2012 444 22 152 270 2011 372 19 130 222 2010 500 450 400 82 111 310 16 116 178 2009 253 13 98 142 2008 203 10 SOURCE: China Pharmaceutical Association; NHFPC statistical yearbook; McKinsey analysis Sales in Chinas hospital pharmaceutical market by hospital class1 RMB billions Class IClass IIClass III Value share by ho
